Roche has announced plans to buy U.S. cancer drugmaker Ignyta Inc for $1.7 billion. The move is meant to increase the company's global oncology portfolio.
Ignyta's operations will continue in San Diego alongside its study of entrectinib, the company's most advanced drug.
The deal is expected to close in the first half of 2018.
Read the CNBC report